Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bec2 + bcg
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intravenous, Subcutaneous (bcg, Standard Route)
01
Overview
**BEC2 + BCG** is a combination immunotherapeutic regimen consisting of **BEC2**, a murine (mouse-derived) anti-idiotypic monoclonal antibody that mimics the GD3 ganglioside, and **BCG** (Bacillus Calmette-Guérin), a live attenuated strain of Mycobacterium bovis commonly used as an immunostimulant. BEC2 acts as a surrogate antigen for the GD3 ganglioside, stimulating the immune system against tumors expressing GD3 (notably of neuroectodermal origin, such as small-cell lung cancer and melanoma). BCG enhances immune reactivity at the site of administration. Clinical studies have investigated the combination as an adjuvant vaccine in patients with limited-disease small-cell lung cancer (SCLC) post-chemotherapy/radiation, and in melanoma, aiming to induce humoral and cellular immune responses against tumor-associated GD3. However, phase III data showed that the combination did not prolong survival in SCLC overall, though patients who mounted a measurable antibody response may have benefited. The primary adverse effects were mild and included local injection site reactions and transient flu-like symptoms[2][4].
- Other names
- bec2 + bacillus calmette-guerinbec2/bcg
02
Targets
GD3 (Ganglioside GD3)
Beyond the preview
Go deeper on bec2 + bcg.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bec2 + bcg.